Pacheco Fabio J, Servin Jacqueline, Dang David, Kim Jim, Molinaro Christine, Daniels Tracy, Brown-Bryan Terry A, Imoto-Egami Mizue, Casiano Carlos A
Loma Linda University School of Medicine, Loma Linda, California 92350, USA.
Arthritis Rheum. 2005 Jul;52(7):2133-45. doi: 10.1002/art.21147.
Autoantibodies to DNA topoisomerase I (topo I) are associated with diffuse systemic sclerosis (SSc), appear to be antigen driven, and may be triggered by cryptic epitopes exposed during in vivo topo I fragmentation. These autoantibodies recognize topo I and fragments of this autoantigen generated during apoptosis and necrosis. We undertook this study to determine whether lysosomal cathepsins are involved in topo I fragmentation during necrosis.
Topo I cleavage during necrosis was assessed by immunoblotting of lysates from L929 fibroblasts exposed to tumor necrosis factor alpha (TNFalpha) and the broad caspase inhibitor Z-VAD-FMK, and by immunoblotting of lysates from endothelial cells treated with HgCl2. Purified topo I and L929 nuclei were incubated with cathepsins B, D, G, H, and L, and topo I cleavage was detected by immunoblotting. The intracellular localization of cathepsin L activity and topo I in necrotic cells was examined using fluorescence microscopy.
Treatment of L929 cells with TNFalpha and Z-VAD-FMK induced caspase-independent cell death with necrotic morphology. This cell death involved topo I cleavage into fragments of approximately 70 kd and 45 kd. This cleavage profile was reproduced in vitro by cathepsins L and H and was inhibited by the cathepsin L inhibitor Z-FY-CHO. During necrosis, cathepsin L activity diffused from lysosomes into the cytoplasm and nucleus, whereas topo I partially relocalized to the cytoplasm. Z-FY-CHO delayed necrosis and partially blocked topo I cleavage. The topo I cleavage fragments were also detected in necrotic endothelial cells and recognized by SSc sera containing anti-topo I antibodies.
These results implicate cathepsins, particularly cathepsin L, in the cleavage of topo I during necrosis. This cleavage may generate potentially immunogenic fragments that could trigger anti-topo I immune responses in SSc.
抗DNA拓扑异构酶I(拓扑异构酶I)自身抗体与弥漫性系统性硬化症(SSc)相关,似乎是抗原驱动的,并且可能由体内拓扑异构酶I片段化过程中暴露的隐蔽表位触发。这些自身抗体识别拓扑异构酶I以及在凋亡和坏死过程中产生的该自身抗原片段。我们进行这项研究以确定溶酶体组织蛋白酶是否参与坏死过程中的拓扑异构酶I片段化。
通过对暴露于肿瘤坏死因子α(TNFα)和泛半胱天冬酶抑制剂Z-VAD-FMK的L929成纤维细胞裂解物进行免疫印迹,以及对用HgCl2处理的内皮细胞裂解物进行免疫印迹,评估坏死过程中的拓扑异构酶I切割。将纯化的拓扑异构酶I和L929细胞核与组织蛋白酶B、D、G、H和L一起孵育,并通过免疫印迹检测拓扑异构酶I切割。使用荧光显微镜检查组织蛋白酶L活性和拓扑异构酶I在坏死细胞中的细胞内定位。
用TNFα和Z-VAD-FMK处理L929细胞诱导了具有坏死形态的非半胱天冬酶依赖性细胞死亡。这种细胞死亡涉及拓扑异构酶I切割成约70kd和45kd的片段。这种切割模式在体外由组织蛋白酶L和H重现,并被组织蛋白酶L抑制剂Z-FY-CHO抑制。在坏死过程中,组织蛋白酶L活性从溶酶体扩散到细胞质和细胞核,而拓扑异构酶I部分重新定位于细胞质。Z-FY-CHO延迟坏死并部分阻断拓扑异构酶I切割。在坏死的内皮细胞中也检测到拓扑异构酶I切割片段,并被含有抗拓扑异构酶I抗体的SSc血清识别。
这些结果表明组织蛋白酶,特别是组织蛋白酶L,参与坏死过程中拓扑异构酶I的切割。这种切割可能产生潜在的免疫原性片段,从而在SSc中引发抗拓扑异构酶I免疫反应。